Everest Medicines Expands Strategic Investment in I-MAB
1. Everest invests $30.9 million to hold 16.1% in I-Mab. 2. I-Mab's givastomig shows an 83% response rate in gastric cancer trials. 3. Synergistic partnership could enhance drug development for both companies. 4. New investment indicates confidence in I-Mab's clinical capabilities. 5. The offering raises approximately $65 million for I-Mab's plans.